viewLexaria Bioscience Corp.

Lexaria Bio Science and partner Altria complete Phase One of the development program

Lexaria BioScience (OTCQX: LXRP- CSE: LXX) CEO Chris Bunka joined Steve Darling from Proactive Vancouver with news the company has seen their Phase One research and development program of oral forms of nicotine delivery finish with Altria Ventures.

Bunka says everything went as planned and now Altria has exercised its right to activate the "First Warrant Tranche Trigger and now has 90 days to provide that payment to retain its current exclusivity in the US market for DehydraTECH.

Quick facts: Lexaria Bioscience Corp.

Price: 0.25 CAD

Market: CSE
Market Cap: $22.51 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...


Lexaria receives ethics board ok to launch human study with DehydraTech for...

Lexaria Bioscience (CSE: LXX-OTCQX: LXRP) CEO Chris Bunka joined Steve Darling from Proactive with news the company has received ethics board approval to conduct a pilot human pharmacokinetic exploratory study of antiviral drugs that have previously been studied against other coronavirus...

3 weeks, 5 days ago

2 min read